Stay updated on Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial
Sign up to get notified when there's something new on the Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial page.

Latest updates to the Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial page
- CheckyesterdayChange DetectedThe site footer revision changes from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check8 days agoChange DetectedThe site revision label in the footer changed from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check28 days agoChange DetectedNew site revision entry v3.7.0 was added to the history, replacing the previous v3.6.6. This reflects an interface/version update in the study history timeline.SummaryDifference0.1%

- Check49 days agoChange DetectedThe study record history now shows the latest revision as v3.6.6, replacing the previous v3.6.5. This reflects an update to the ClinicalTrials.gov record display for the nct03836066 page.SummaryDifference0.1%

- Check71 days agoChange DetectedA new revision entry v3.6.5 is added to the study record history, superseding the previous v3.6.4.SummaryDifference0.1%

- Check85 days agoChange DetectedA new revision entry v3.6.4 is added to the history. The previous v3.6.3 is removed from the list, updating the page's version history.SummaryDifference0.1%

Stay in the know with updates to Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial page.